ArticleInternational journal of environmental research and public health2025
Comorbidity Prevalence in Prediabetes and Type 2 Diabetes: A Cross-Sectional Study in a Predominantly Hispanic U.S.-Mexico Border Population.
Article in International journal of environmental research and public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Type 2 diabetes and prediabetes are associated with a higher risk of several health conditions. We conducted a cross-sectional study to compare the prevalence of comorbidities among 88,724 adults with prediabetes and 12,071 adults with type 2 diabetes in El Paso, Texas, using data from the Paso del Norte Health Information Exchange (PHIX) from 1 January 2021, to 31 January 2023. We estimated prevalence ratios (aPR) adjusted for age decade, gender, and Hispanic ethnicity. Individuals with prediabetes, compared to type 2 diabetes, had lower adjusted prevalence of circulatory (59.1% vs. 80.4%; aPR = 0.82 [95% CI: 0.81-0.84]), genitourinary (44.9% vs. 50.5%; aPR = 0.97 [0.96-0.99]), respiratory (32.0% vs. 35.7%; aPR = 0.94 [0.92-0.97]), neurological (27.4% vs. 32.8%; aPR = 0.91 [0.88-0.94]), blood (21.2% vs. 30.5%; aPR = 0.77 [0.75-0.80]), mental (19.5% vs. 26.1%; aPR = 0.72 [0.69-0.75]), infectious (12.8% vs. 21.5%; aPR = 0.63 [0.60-0.66]), skin (12.2% vs. 14.8%; aPR = 0.82 [0.78-0.86]), and COVID-19 (10.2% vs. 11.9%; aPR = 0.86 [0.81-0.91]) diseases/conditions. Adjusted prevalence was higher among those with prediabetes for musculoskeletal (53.8% vs. 47.0%; aPR = 1.19 [1.17, 1.21]), ear (18.4% vs. 12.9%; aPR = 1.54 [1.47-1.60]), eye (11.1% vs. 7.8%; aPR = 1.52 [1.43, 1.61]), digestive (44.0% vs. 44.0%; aPR = 1.02 [1.00-1.05]), and neoplastic (14.4% vs. 14.5%; aPR = 1.12 [1.06-1.17]) diseases/conditions. People with prediabetes in El Paso, Texas, had a lower prevalence of most comorbidities than those with type 2 diabetes, suggesting that preventing prediabetes from progressing to type 2 diabetes could have a beneficial impact on comorbid disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.